does retatrutide give you heartburn Half Life: A Doctor Explains in Simple Terms A Potential Breakthrough in Weight

A recent open label trial compared the efficacy of drugs currently used to lower ICP in IIH (amiloride, furosemide, spironolactone and topiramate) and found a marginal reduction in ICP with no difference between drugs [11]

Biochem Pharmacol 229:116471 Kelly CA, Sipos JA (2024) Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists

Theyre not in their head. And theyre not something we get to dismiss just because weight is moving in the right direction

The North America GLP-1 receptor agonist market dominated the revenue with 75.46% share in 2025, supported by a high prevalence of metabolic disorders, early adoption of novel therapeutics, and a well-established healthcare infrastructure

For more information, please contact us or schedule an appointment online

Capital Blue Cross and its affiliated companies believe this health education resource provides useful information but does not assume any liability associated with its use.